Vivos Therapeutics Files 8-K
Ticker: VVOS · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, reporting
TL;DR
Vivos Therapeutics filed a standard 8-K, no major news.
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on October 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial details or new material events beyond the standard reporting requirements for the period ending October 24, 2025. The company's principal executive offices are located in Littleton, Colorado.
Why It Matters
This 8-K filing indicates routine corporate reporting by Vivos Therapeutics, Inc. without disclosing new material events or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would indicate a change in risk.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- October 24, 2025 (date) — Date of earliest event reported
- Littleton, Colorado (location) — Principal executive offices
- 001-39796 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Vivos Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of October 24, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 24, 2025.
Where are Vivos Therapeutics, Inc.'s principal executive offices located?
Vivos Therapeutics, Inc.'s principal executive offices are located at 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120.
What is the Commission File Number for Vivos Therapeutics, Inc.?
The Commission File Number for Vivos Therapeutics, Inc. is 001-39796.
Does this filing disclose any specific new financial results or material events?
No, this filing indicates "Other Events" and "Financial Statements and Exhibits" but does not disclose specific new financial results or material events beyond standard reporting.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-10-24 17:20:50
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex5-1.htm (EX-5.1) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-019359.txt ( ) — 218KB
- vvos-20251024.xsd (EX-101.SCH) — 3KB
- vvos-20251024_lab.xml (EX-101.LAB) — 33KB
- vvos-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (720) 399-9322 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Information On October 24, 2025, Vivos Therapeutics, Inc. (the " Company ") filed a prospectus supplement to increase the aggregate offering price of the shares (the " Shares ") of the Company's common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., dated February 14, 2025. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Ellenoff Grossman & Schole LLP relating to the legality of the issuance and sale of the Shares. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Ellenoff Grossman & Schole LLP 23.1 Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: October 24, 2025 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer